ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption
ICON plc (NASDAQ: ICLR) has released findings from a global survey of 101 biotech and pharma professionals regarding AI and digital innovation adoption in clinical research. The survey reveals sustained optimism about digital tools, with an 82% agreement on improved R&D investment returns and 76% on enhanced product safety and efficacy.
Key findings show a 34% average increase in digital tools investment over the past five years, with 88% of respondents planning further increases in the next two years. However, implementation remains selective, with 70% of organizations either piloting or selectively using AI, and only 13% having fully implemented comprehensive AI programs.
The survey identifies challenges in broader adoption, including concerns about patient safety, data integrity, and regulatory compliance. Despite these challenges, ICON emphasizes the need for comprehensive strategic approaches to maximize digital technologies in R&D.
ICON plc (NASDAQ: ICLR) ha pubblicato i risultati di un sondaggio globale condotto su 101 professionisti del biotecnologico e farmaceutico riguardo all'adozione dell'AI e dell'innovazione digitale nella ricerca clinica. Il sondaggio rivela un ottimismo costante riguardo agli strumenti digitali, con un accordo del 82% su un miglior ritorno sugli investimenti in R&S e del 76% su una maggiore sicurezza ed efficacia dei prodotti.
I risultati chiave mostrano un aumento medio del 34% negli investimenti in strumenti digitali negli ultimi cinque anni, con l'88% degli intervistati che pianifica ulteriori aumenti nei prossimi due anni. Tuttavia, l'implementazione rimane selettiva, con il 70% delle organizzazioni che sta testando o utilizzando selettivamente l'AI, e solo il 13% ha completamente implementato programmi AI completi.
Il sondaggio individua le sfide per una maggiore adozione, includendo preoccupazioni riguardo a sicurezza dei pazienti, integrità dei dati e conformità normativa. Nonostante queste sfide, ICON sottolinea la necessità di approcci strategici completi per massimizzare le tecnologie digitali nella R&S.
ICON plc (NASDAQ: ICLR) ha publicado los hallazgos de una encuesta global a 101 profesionales de biotecnología y farmacéutica sobre la adopción de la IA y la innovación digital en la investigación clínica. La encuesta revela un optimismo sostenido acerca de las herramientas digitales, con un 82% de acuerdo en que mejora el retorno de la inversión en I+D y un 76% en que mejora la seguridad y eficacia de los productos.
Los hallazgos clave muestran un aumento medio del 34% en la inversión en herramientas digitales en los últimos cinco años, y el 88% de los encuestados planea aumentar aún más en los próximos dos años. Sin embargo, la implementación sigue siendo selectiva, con el 70% de las organizaciones que están pilotando o utilizando IA de manera selectiva, y solo el 13% ha implementado completamente programas de IA integrales.
La encuesta identifica los desafíos para una adopción más amplia, incluyendo preocupaciones sobre la seguridad del paciente, la integridad de los datos y el cumplimiento normativo. A pesar de estos desafíos, ICON enfatiza la necesidad de enfoques estratégicos integrales para maximizar las tecnologías digitales en I+D.
ICON plc (NASDAQ: ICLR)는 임상 연구에서 AI 및 디지털 혁신 채택에 관한 101명의 생명공학 및 제약 전문가를 대상으로 한 글로벌 설문 조사 결과를 발표했습니다. 이 설문 조사는 디지털 도구에 대한 지속적인 낙관주의를 보여주며, R&D 투자 수익 개선에 대한 82%의 동의와 제품 안전성 및 효능 향상에 대한 76%의 동의가 있었습니다.
주요 결과는 지난 5년 동안 디지털 도구 투자 평균 34% 증가를 보여주며, 응답자의 88%가 향후 2년 내에 추가 증가를 계획하고 있다고 합니다. 그러나 실행은 선택적이며, 70%의 조직이 AI를 파일럿하거나 선택적으로 사용하고 있으며, 단 13%만이 포괄적인 AI 프로그램을 완전히 구현했습니다.
조사는 더 넓은 채택에서의 도전 과제를 식별하며, 여기에는 환자 안전, 데이터 무결성 및 규정 준수에 대한 우려가 포함됩니다. 이러한 도전에도 불구하고, ICON은 R&D에서 디지털 기술을 극대화하기 위한 포괄적인 전략적 접근의 필요성을 강조합니다.
ICON plc (NASDAQ: ICLR) a publié les résultats d'une enquête mondiale auprès de 101 professionnels de la biotechnologie et de l'industrie pharmaceutique concernant l'adoption de l'IA et des innovations digitales dans la recherche clinique. L'enquête révèle un optimisme soutenu concernant les outils numériques, avec 82 % d'accord sur l'amélioration des retours sur investissement en R&D et 76 % sur l'amélioration de la sécurité et de l'efficacité des produits.
Les résultats clés montrent une augmentation moyenne de 34 % des investissements dans les outils numériques au cours des cinq dernières années, 88 % des répondants prévoyant d'augmenter encore ces investissements au cours des deux prochaines années. Cependant, la mise en œuvre reste sélective, 70 % des organisations pilotant ou utilisant sélectivement l'IA, et seulement 13 % ayant entièrement mis en place des programmes d'IA complets.
L'enquête identifie des défis à une adoption plus large, y compris des préoccupations concernant la sécurité des patients, l'intégrité des données et la conformité réglementaire. Malgré ces défis, ICON met l'accent sur la nécessité d'approches stratégiques complètes pour maximiser les technologies numériques en R&D.
ICON plc (NASDAQ: ICLR) hat Ergebnisse einer globalen Umfrage unter 101 Biotech- und Pharma-Profis zur Einführung von KI und digitalen Innovationen in der klinischen Forschung veröffentlicht. Die Umfrage zeigt einen nachhaltigen Optimismus bezüglich digitaler Werkzeuge, mit 82% Zustimmung zu verbesserten Renditen von F&E-Investitionen und 76% zu erhöhter Produktsicherheit und -effizienz.
Wesentliche Erkenntnisse zeigen eine durchschnittliche Erhöhung der Investitionen in digitale Werkzeuge um 34% in den letzten fünf Jahren, wobei 88% der Befragten weitere Erhöhungen in den nächsten zwei Jahren planen. Die Umsetzung bleibt jedoch selektiv, da 70% der Organisationen entweder KI testen oder selektiv einsetzen und nur 13% umfassende KI-Programme vollständig implementiert haben.
Die Umfrage identifiziert Herausforderungen für eine breitere Annahme, einschließlich Bedenken hinsichtlich Patientensicherheit, Datenintegrität und regulatorischer Compliance. Trotz dieser Herausforderungen betont ICON die Notwendigkeit umfassender strategischer Ansätze zur Maximierung digitaler Technologien in der F&E.
- None.
- None.
Survey spotlights shifting expectations and more measured pace of innovation as use of digital solutions matures within the biotech and pharma industry
Respondents revealed that attitudes towards the potential impact of digital tools and AI solutions remain relatively positive. Sponsors’ optimism about their potential to improve R&D productivity has grown +
They agreed that digital tools could improve return on R&D investments (
In its new whitepaper on these findings, “Digital disruption: Surveying the industry's evolving landscape”, ICON shares how and why companies should take a more integrated approach to digital tools and AI.
Tom O’Leary, Chief Information Officer, ICON commented: “Over the last five years the life sciences industry has gained a greater appreciation of the level of investment required to capitalise on the potential of AI and digital tools. Digital innovation in clinical research can support more efficient and less burdensome trials. But in order to fully realise the productivity gains, companies must embrace what these tools can offer at a broad level, as opposed to one-off applications.”
The survey found that investment in AI and digital tools is significant. Over the past five years, the average total investment increase in digital tools is estimated at
However, at this stage in their implementation journeys, new technologies are being used more in single development programs, with organisations not yet incorporating them at a wider scale. A large majority of respondents (
Respondents now have a clearer view of the challenges around large scale adoption and implementation within clinical development. The primary issues cited as delaying broader digital adoption included concerns around patient safety, data integrity, and regulatory compliance.
Tom O’Leary commented, “Comprehensive and strategic approaches are required to navigate complexity and maximise digital technologies in R&D, despite some organisations’ understandable hesitations due to potential risks. Watching and waiting whilst others test, assess and refine is a safe bet, but it slows the overall pace of digital innovation.
“Tools designed specifically for clinical trials are better placed to address the unique challenges and regulatory demands. With an understanding of these complexities, in addition to the required investment and approaches, the benefits of AI and digital tools in R&D can be realised sooner. ICON’s comprehensive suite of solutions can enhance operational efficiencies in drug development to facilitate successful trials that result in better outcomes for sites and patients.”
ICON’s new whitepaper sets out how companies can address these barriers across increasingly complex and costly trials and how to avoid operational disruptions associated with digital transformation. It shares considerations for navigating regulatory uncertainties around new technology implementation.
For further information please visit ICONplc.com/digitaldisruption.
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in
ICON/ICLR-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205058924/en/
Claire Quinn, Corporate Communications, ICON
+353 87 4066091
claire.quinn@iconplc.com
Lisa Henry, Weber Shandwick (PR adviser)
+44 7785 458203
lhenry@webershandwick.com
Source: ICON plc
FAQ
What percentage increase in digital tools investment did ICON's survey reveal for the past 5 years?
How many biotech and pharma professionals participated in ICON's 2023 AI adoption survey?
What percentage of organizations in ICON's survey have fully implemented AI programs?
What are the main challenges delaying digital adoption according to ICON's survey?
What percentage of ICON survey respondents expect to increase AI investment in the next 1-2 years?
